NSCLC patients harboring an EGFR-activating mutation develop acquired resistance after a median of 9–11 months from the beginning of treatment with TKI, such as erlotinib and gefitinib [51, 52]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.